Read by QxMD icon Read


C Terrier, J-E Terrier
INTRODUCTION: In August 2015, the US Food and Drug Administration (FDA) has approved Addyi(®) (flibanserin) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in pre-menopausal women. We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug in women with HSDD. PATIENTS AND METHODS: A systematic literature review from the PubMed database search was carried out until April 2016 using the following keywords: "HSDD", "flibanserin", "sexual desire" and "ransomised controlled trial"...
September 20, 2016: Progrès en Urologie
Anita Clayton, Robert Pyke
No abstract text is available yet for this article.
September 20, 2016: Journal of Sex & Marital Therapy
Paige E Tucker, Christobel Saunders, Max K Bulsara, Jason Jit-Sun Tan, Stuart G Salfinger, Helena Green, Paul A Cohen
OBJECTIVES: To investigate the prevalence of sexual dysfunction in women with a history of breast cancer following risk-reducing salpingo-oophorectomy (RRSO). A secondary objective was to examine the effect of a prior diagnosis of breast cancer, and other factors, on sexuality and quality of life (QoL) outcomes. STUDY DESIGN: Cross-sectional study of 119 women who underwent RRSO between 2009 and 2014. MAIN OUTCOME MEASURES: Data were collected via a questionnaire comprising demographic information and validated measures of sexual function, sexual distress, relationship satisfaction, body image, psychological stress, menopause symptoms and general quality of life...
September 1, 2016: Breast: Official Journal of the European Society of Mastology
Heidi Collins Fantasia
Female hypoactive sexual desire disorder (HSDD) is one type of sexual problem that can affect women. It is characterized by low or absent sexual desire that cannot be attributed to another cause and results in difficulty in interpersonal relationships. HSDD is not well understood, and women may not report symptoms of difficulties to their health care providers. In August 2015, the U.S. Food and Drug Administration approved flibanserin, a nonhormonal oral medication for the treatment of HSDD in premenopausal women...
June 2016: Nursing for Women's Health
Carlos Eduardo Paiva, Fabiana Faria Rezende, Bianca Sakamoto Ribeiro Paiva, Edmundo Carvalho Mauad, Gustavo Zucca-Matthes, Estela Cristina Carneseca, Kari Juhani Syrjänen, Leslie R Schover
Sexual dysfunction is a common and distressing consequence of breast cancer (BC) treatment. In the present study, we investigated the sexual functioning of BC patients and its association with women's personal characteristics and cancer treatments. In this cross-sectional study, sexual function was assessed using the Female Sexual Function Index (FSFI). The health-related quality of life (HRQOL) was measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and its breast module BR-23...
June 3, 2016: Archives of Sexual Behavior
Jae Hong Sang, Tae-Hee Kim, Soo Ah Kim
There have been several products developed for male sexual dysfunction. However, developing agents for female sexual dysfunction is lagging behind for various reasons. Sildenafil citrate (Viagra) and Tadalafil (Cialis), which have been prescribed for male sexual function disorders, are known to act on vessels.[1] On the other hand, flibanserin is thought to act on brain. Flibanserin has been approved by U. S. Food and Drug Administration (FDA) for treatment of hypoactive sexual desire disorder (HSDD) of premenopausal women in 2015, and is expected to be released in South Korea soon...
April 2016: Journal of Menopausal Medicine
Patrick Meyer
Hypoactive sexual desire disorder (HSDD) is a deficiency of sexual desire that causes marked personal or interpersonal distress. It occurs in approximately 1 in 10 adult women. A number of potential contributory factors (hormonal, neurobiological and psychosocial) have been identified. Testosterone plays an excitatory role in sexual desire but the mechanism is not yet well understood. Treatment with testosterone has been shown to improve sexual desire in menopausal women with HSDD. However, there are limited data concerning premenopausal women and long-term safety...
March 16, 2016: Revue Médicale Suisse
Susan H Oakley, J Walther-Liu, C C Crisp, R N Pauls
INTRODUCTION: Female sexual dysfunction affects up to 43% of women in the United States and hypoactive sexual desire disorder (HSDD) is the most common type; however, we lack treatment options showing improvement for this condition. AIMS: To investigate whether acupuncture therapy could improve HSDD. METHODS: Premenopausal women with a primary diagnosis of HSDD were included in a single-arm prospective pilot study that was approved by the institutional review board...
September 2016: Sexual Medicine
J K Smith, L Marciani, D J Humes, S T Francis, P Gowland, R C Spiller
BACKGROUND: The relative importance of peripheral nerve injury or central pain processing in painful diverticular disease (DD) is unclear. Functional magnetic resonance imaging (fMRI) has demonstrated that dysfunctional central pain processing predominates in irritable bowel syndrome (IBS). This study aims to identify anticipatory changes in symptomatic DD (SDD) compared to asymptomatic DD (ADD) and IBS patients. METHODS: Gastrointestinal symptoms and somatization were evaluated via the Patient Health Question-12 Somatic Symptom and the SDD group divided into low (≤6 [LSDD]) and high (≥7 [HSDD]) somatization...
June 2016: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
Loes Jaspers, Frederik Feys, Wichor M Bramer, Oscar H Franco, Peter Leusink, Ellen T M Laan
IMPORTANCE: In August 2015, the US Food and Drug Administration (FDA) approved flibanserin as a treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, despite concern about suboptimal risk-benefit trade-offs. OBJECTIVE: To conduct a systematic review and meta-analysis of randomized clinical trials assessing efficacy and safety of flibanserin for the treatment of HSDD in women. DATA SOURCES: Medical databases (among others, Embase, Medline, Psycinfo) and trial registries were searched from inception to June 17, 2015...
April 2016: JAMA Internal Medicine
Mina Malary, Soghra Khani, Mehdi Pourasghar, Mahmood Moosazadeh, Zeinab Hamzehgardeshi
BACKGROUND: As a mental response to sexual stimuli, sexual desire determines human sexual behavior and represents the cognitive capacity of sexual stimulation, so that avoiding sexual activity has a very negative effect on the discharge of intimacy and joy in couple's relationship and threatens the stability relationship, which can finally end in sexual dissatisfaction and divorce; it may even affect the reproduction. This study, reviews the literature on biopsychosocial determinants of hypoactive sexual desire disorder in women in childbearing ages...
December 2015: Materia Socio-medica
Ximena Vallejos, Christine Wu
OBJECTIVE: To review pivotal clinical trials, pharmacology, contraindications, precautions, and key patient education points of flibanserin for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. DATA SOURCES: A literature search of PubMed using the key words flibanserin and HSDD was conducted in September 2015. There was no time frame to exclude relevant clinical trials. All trials referenced were published between March 2012 and June 2014...
February 11, 2016: Journal of Pharmacy Practice
Zhenli Gao, Diandong Yang, Luxin Yu, Yuanshan Cui
INTRODUCTION: Flibanserin, is a postsynaptic agonist of serotonin receptor 1A and an antagonist of serotonin receptor 2A, has been shown to increase sexual desire and reduce distress in women with hypoactive sexual desire disorder (HSDD). AIM: We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug in women with HSDD. METHODS: A literature review was performed to identify all published randomized double-blind, placebo-controlled trials of flibanserin for the treatment of HSDD...
November 2015: Journal of Sexual Medicine
Kristin Robinson, Jasmine B R Cutler, Nicholas W Carris
OBJECTIVE: To review data regarding flibanserin, a recently approved therapy for hypoactive sexual desire disorder (HSDD). DATA SOURCES: Literature search of MEDLINE (September 1995 to November 2015) was performed using the search term flibanserin. Reference lists from included articles were reviewed for pertinent citations. STUDY SELECTION AND DATA EXTRACTION: We included phase-3 trials of flibanserin as a treatment for HSDD. Four reports of phase-3 trials were included...
February 2016: Annals of Pharmacotherapy
Hylton V Joffe, Christina Chang, Catherine Sewell, Olivia Easley, Christine Nguyen, Somya Dunn, Kimberly Lehrfeld, LaiMing Lee, Myong-Jin Kim, Ashley F Slagle, Julie Beitz
Was the Food and Drug Administration (FDA) approval of flibanserin (Addyi) for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women long overdue? Or was it an error? In the face of divergent views, we at the FDA think it's important to clarify why flibanserin was approved..
January 14, 2016: New England Journal of Medicine
Robert E Pyke, Anita H Clayton
INTRODUCTION: Publications claim efficacy for treatment of hypoactive sexual desire disorder (HSDD) in women with cognitive behavior therapy (CBT) and mindfulness meditation training (MMT). However, no review has evaluated the evidence for these therapies from the rigorous perspective of sexual medicine. AIMS: The aim of this study was to evaluate the published controlled trials of CBT and MMT for disorders of sexual desire from the perspective of sexual medicine standards of control paradigms, risk/benefit ratios, and clinical significance...
December 2015: Journal of Sexual Medicine
Paige E Tucker, Max K Bulsara, Stuart G Salfinger, Jason Jit-Sun Tan, Helena Green, Paul A Cohen
OBJECTIVES: To determine the prevalence of sexual dysfunction in women after risk-reducing salpingo-oophorectomy (RRSO) and to assess factors which may influence sexual wellbeing following this procedure. METHODS: This work is a cross-sectional study of women who underwent RRSO at a tertiary gynecologic oncology unit between January 2009 and October 2014. Data collection involved a comprehensive questionnaire including validated measures of sexual function, sexual distress, relationship satisfaction, body image, impact of event, menopause specific quality of life, and general quality of life...
January 2016: Gynecologic Oncology
Sheryl A Kingsberg, Anita H Clayton, James G Pfaus
How a woman responds to sexual cues is highly dependent on a number of distinct, yet related, factors. Researchers have attempted to explain the female sexual response for decades, but no single model reigns supreme. Proper female sexual function relies on the interplay of somatic, psychosocial and neurobiological factors; misregulation of any of these components could result in sexual dysfunction. The most common sexual dysfunction disorder is hypoactive sexual desire disorder (HSDD). HSDD is a disorder affecting women across the world; a recent in-person diagnostic interview study conducted in the USA found that an estimated 7...
November 2015: CNS Drugs
Sabina Sarin, Rhonda Amsel, Yitzchak M Binik
Research indicates that desire and arousal problems are highly interrelated in women. Therefore, hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD) were removed from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and a new diagnostic category, female sexual interest/arousal disorder (FSIAD), was created to include both arousal and desire difficulties. However, no research has tried to distinguish these problems based on psychosocial-physiological patterns to identify whether unique profiles exist...
July 2016: Journal of Sex Research
Emma D Deeks
Flibanserin (Addyi™) is chemically described as a benzimidazole and is being developed by Sprout Pharmaceuticals for the treatment of hypoactive sexual desire disorder (HSDD). The drug has a high affinity for serotonin 5-HT1A and 5-HT2A receptors (5-HT1A agonist/5-HT2A antagonist) and is believed to treat HSDD by increasing levels of dopamine and noradrenaline and lowering levels of serotonin in the brain. Flibanserin has been approved in the USA for the treatment of premenopausal women with acquired, generalized HSDD...
October 2015: Drugs
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"